Table 4.
Clinical Characteristics Associated Factors with Recurrence-free Survival
| Variable | Total (N = 179) |
BRCA (−) (N = 120) |
BRCA (+) (N = 59) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 95% Confidence interval |
P | Median | 95% Confidence interval |
P | Median | 95% Confidence interval |
P | ||||
| Lower bound | Upper bound | Lower bound | Upper bound | Lower bound | Upper bound | |||||||
| RFS (months) | 47.7 | 40.4 | 55.0 | 49.2 | 40.6 | 57.8 | 43.7 | 34.8 | 52.6 | |||
| Age (years) | 0.970 | 0.818 | 0.873 | |||||||||
| ≤48 | 46.3 | 34.2 | 58.4 | 46.3 | 31.2 | 61.4 | 46.5 | 20.1 | 72.9 | |||
| >48 | 48.1 | 39.9 | 56.2 | 51.4 | 30.9 | 72.0 | 41.8 | 33.1 | 50.5 | |||
| Group of age at DX | <0.0001 | <0.0001 | <0.0001 | |||||||||
| ≤34 | 14.7 | 7.4 | 22.1 | 16.3 | 12.3 | 20.2 | – | – | – | |||
| 35–44 | 51.7 | 42.5 | 61.0 | 51.8 | 31.7 | 72.0 | 46.5 | 20.5 | 72.5 | |||
| 45–54 | 49.0 | 29.1 | 68.9 | 57.7 | 34.6 | 80.8 | 47.7 | 34.7 | 60.7 | |||
| 55–64 | 61.4 | 32.3 | 90.4 | 51.4 | 25.0 | 77.9 | 37.2 | 0.0 | 85.1 | |||
| ≥65 | 43.7 | 20.7 | 66.7 | 30.4 | 22.8 | 69.2 | 56.6 | 36.0 | 77.2 | |||
| Clinical stage at Dx | 0.001 | 0.001 | 0.199 | |||||||||
| I & II | 96.9 | 86.6 | 107.3 | 96.9 | 86.5 | 107.3 | NR | NR | NR | |||
| III (A & B) | 46.3 | 21.2 | 71.4 | 38.4 | 16.8 | 60.0 | 59.6 | 5.4 | 113.8 | |||
| IIIC | 43.4 | 28.5 | 58.2 | 50.8 | 37.7 | 63.9 | 37.2 | 23.2 | 51.1 | |||
| IV | 41.8 | 23.9 | 59.6 | 28.5 | 8.2 | 48.9 | 43.7 | 34.4 | 49.2 | |||
| Histology | 0.004 | 0.004 | <0.0001 | |||||||||
| Clear cells | 40.3 | 26.7 | 53.8 | 40.3 | 26.5 | 54.1 | – | – | – | |||
| HGSP | 37.2 | 27.0 | 47.3 | 33.4 | 19.4 | 47.5 | 40.1 | 30.7 | 49.5 | |||
| LGSP | 33.8 | 28.5 | 84.6 | 62.5 | 16.3 | 132.3 | – | – | – | |||
| Endometroid | 91.8 | 50.7 | 132.8 | 96.9 | 86.2 | 107.6 | – | – | – | |||
| Adenocarcinoma | 88.1 | 69.7 | 106.5 | NR | NR | NR | 79.5 | 29.2 | 129.8 | |||
| Mixed | 54.5 | 33.6 | 75.4 | 102.9 | 43.6 | 110.9 | 54.5 | 37.2 | 71.9 | |||
| Double primary malignancy | 0.887 | 0.720 | 0.897 | |||||||||
| Negative | 47.7 | 40.4 | 54.9 | 49.2 | 41.4 | 57.0 | 43.7 | 35.0 | 52.3 | |||
| Positive | 80.6 | 11.6 | 149.5 | NR | NR | NR | 34.5 | 29.2 | 96.0 | |||
| Breast/ovarian | 34.5 | 4.7 | 93.5 | 0.868 | NR | NR | NR | – | 34.5 | 29.2 | 96.0 | – |
| Endometrium/ovarian | NR | NR | NR | NR | NR | NR | – | – | – | |||
| 1° line treatment | 0.793 | 0.875 | 0.937 | |||||||||
| CBP/TXL per week | 42.8 | 32.5 | 53.1 | 42.8 | 3.4 | 49.4 | 40.1 | 9.2 | 71.0 | |||
| CBP/TXL 3 weeks | 46.5 | 37.5 | 55.4 | 49.2 | 6.3 | 61.6 | 43.7 | 32.3 | 55.1 | |||
| Other | 61.4 | 9.2 | 113.5 | 61.4 | 26.6 | 113.5 | – | – | – | |||
| Line of treatment | 0.043 | 0.023 | 0.659 | |||||||||
| 1° Line | 62.3 | 49.8 | 74.9 | 62.5 | 48.6 | 76.4 | 34.5 | 21.0 | 48.0 | |||
| 2° Line | 47.7 | 37.9 | 57.4 | 46.3 | 23.0 | 69.6 | 43.4 | 20.9 | 65.9 | |||
| ≥3° Line | 37.6 | 30.02 | 45.21 | 33.8 | 20.8 | 46.8 | 47.7 | 30.0 | 65.4 | |||
CHF = cancer family history.